A Human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth In Vitro and In Vivo

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 594-603

  Chen, Renjie ^a   Zhang, Dawei ^a   Mao, Yuan ^b   Zhu, Jin ^a,c   Ming, Hao ^d   Wen, Juan ^a   Ma, Jun ^e   Cao, Qing ^a   Lin, Hong ^a   Tang, Qi ^a   Liang, Jie ^a   Feng, Zhenqing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Department of Otolaryngology Head and Neck Surgery   (China)

^c Huadong Medical Institute of Biotechniques   (China)

^d XUZHOU CENTRAL HOSPITAL   (China)

^e WANNAN MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; IMMUNOGLOBULIN F(AB) FRAGMENT; LATENT MEMBRANE PROTEIN 1; MITOMYCIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOMYCIN; NASOPHARYNGEAL NEOPLASMS; PEPTIDE LIBRARY; TUMOR BURDEN; VIRAL MATRIX PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859382989     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0725     Document Type: Article

References (34)

1. De-Thé G, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, et al. Epidemiological evidence for causal relationship between Epstein- Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 1978;274:756-61. (Pubitemid 8406152)
2. Morris MA, Dawson CW, Young LS. Role of the Epstein-Barr virusencoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol 2009;5:811-25.
3. Hu LF, Chen F, Zhen QF, Zhang YW, Luo Y, Zheng X, et al. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and nonexpressing nasopharyngeal carcinomas. Eur J Cancer 1995;31A:658-60.
4. Smee RI, Meagher NS, Broadley K, Ho T, Williams JR, Bridger GP. Recurrent nasopharyngeal carcinoma: current management approaches. Am J Clin Oncol 2010;33:469-73.
5. Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, et al. Cloning and characterization of the latentmembrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 1992;7:2131-40.
6. Tarrand JJ, Keating MJ, Tsimberidou AM, O'Brien S, LaSala RP, Han XY, et al. Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer 2010:116;880-7.
7. Zhang DW, Zhu J, Chen RJ, Feng ZQ. Expression and purification of GST-LMP-1 extracellular domain fusion protein of EB virus. Acta Univ Med Nanjing 2008;28:420-3.
8. Jiao YJ, Zhao P, Zhu J, Grabinski T, Feng Z, Guan X, et al. Construction of human naive Fab library and characterization of anti-met Fab fragment generated from the library. Mol Biotechnol 2005;31:41-54. (Pubitemid 41208421)
9. Ding L, Li LL, Yang J, Tao YG, Ye M, Shi Y, et al. Epstein-Barr virus encoded latent membrane protein 1 modulates nuclear translocation of telomerase reverse transcriptase protein by activating nuclear factor-kappaB p65 in human nasopharyngeal carcinoma cells. Int J Biochem Cell Biol 2005;37:1881-9. (Pubitemid 40961672)
10. Dantas-Barbosa C, Faria FP, Brigido MM, Maranhão AQ. Isolation of osteosarcoma-associated human antibodies from a combinatorial Fab phage display library. J Biomed Biotechnol 2009;2009:157531.
11. Sagane K, Ishihama Y, Sugimoto H. LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11. Int J Biol Sci 2008;4:387-96.
12. Saini D, Kala M, Jain V, Sinha S. Targeting the active site of the placental isozyme of alkaline phosphatase by phage-displayed scFv antibodies selected by a specific uncompetitive inhibitor. BMC Biotechnol 2005;5:33.
13. Shao W, Zhao S, Liu Z, Zhang J, Ma S, Sato JD, et al. Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun 2006;349:816-24. (Pubitemid 44344585)
14. Lee G, Ge B. Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor. Cancer Immunol Immunother 2010;59:1011-9.
15. Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, et al. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with paclitaxel or trastuzumab in breast and ovarian cancer xenograft models. Cancer Immunol Immunother 2011;60:339-48.
16. Kitamura K, Takahashi T, Kotani T, Miyagaki T, Yamaoka N, Tsurumi H, et al. Local administration of monoclonal antibody-drug conjugate: a new strategy to reduce the local recurrence of colorectal cancer. Cancer Res 1992;52:6323-8.
17. Kanellos J, McKenzie IF, Pietersz GA. Intratumour therapy of solid tumours with ricin-antibody conjugates. Immunol Cell Biol 1989;67:89-99. (Pubitemid 19175580)
18. Jarvinen TA, Liu ET. HER-2/neu and topoisomerase IIa in breast cancer. Breast Cancer Res Treat 2003;78:299-311. (Pubitemid 36543210)
19. Liu C, Strobl JS, Bane S, Schilling JK, McCracken M, Chatterjee SK, et al. Design, synthesis, and bioactivities of steroid linked taxol analogues as potential targeted drugs for prostate and breast cancer. J Nat Prod 2004;67:152-9. (Pubitemid 38282901)
20. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5:147-59.
21. Liu G, Yao K, Wang B, Chen Y, Zhou F, Guo Y, et al. Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein. Cell Mol Immunol 2009;6:423-31.
22. Long HM, Parsonage G, Fox CP, Lee SP. Immunotherapy for Epstein-Barr virus-associated malignancies. Drug News Perspect 2010;23:221-8.
23. Hannigan A, Wilson JB. Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition. Mol Cancer 2010;9:184.
24. Klein G, Klein E, Kashuba E. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochem Biophys Res Commun 2010;396:67-73.
25. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988;69:1051-65.
26. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
27. Fang CY, Chang YS, Chow KP, Yu JS, Chang HY. Construction and characterization of monoclonal antibodies specific to Epstein-Barr virus latent membrane protein 1. J Immunol Methods 2004;287:21-30. (Pubitemid 38510206)
28. Lee AW, Law SC, Ng SH, Chan DK, Poon YF, Foo W, et al. Retrospective analysis of nasopharyngeal carcinoma treated during 1976-1985: late complications following megavoltage irradiation. Br J Radiol 1992;65:918-28.
29. Rowe M, Finke J, Szigeti R, Klein G. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J Gen Virol 1988;69:1217-28.
30. Gattenlöhner S, Jörissen H, Huhn M, Vincent A, Beeson D, Tzartos S, et al. Ahuman recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. J Biomed Biotechnol 2010;2010:187621.
31. Fähraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988;42:329-38.
32. Elliott K. Epstein-Barr virus-increasing evidence of a link to carcinoma. N Engl J Med 1995;333:724-6.
33. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992;66:2689-97.
34. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.